Atherosclerotic plaque epigenetic age acceleration is characterized by mesenchymal reprogramming and poor prognosis
Robin J. G. Hartman, View ORCID ProfileErnest Diez Benavente, View ORCID ProfileLotte Slenders, View ORCID ProfileArjan Boltjes, Barend M. Mol, View ORCID ProfileGert J. de Borst, View ORCID ProfileDominique P. V. de Kleijn, View ORCID ProfileKoen H. M. Prange, View ORCID ProfileMenno P. J. de Winther, View ORCID ProfileJohan Kuiper, View ORCID ProfileMete Civelek, View ORCID ProfileSander W. van der Laan, Steve Horvath, View ORCID ProfileCharlotte Onland-Moret, View ORCID ProfileMichal Mokry, View ORCID ProfileGerard Pasterkamp, View ORCID ProfileHester M. den Ruijter
doi: https://doi.org/10.1101/2023.02.16.23286067
Robin J. G. Hartman
1Laboratory of Experimental Cardiology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
Ernest Diez Benavente
1Laboratory of Experimental Cardiology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
Lotte Slenders
2Central Diagnostic Laboratory, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
Arjan Boltjes
2Central Diagnostic Laboratory, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
Barend M. Mol
3Department of Vascular Surgery, University Medical Center Utrecht, University Utrecht, Utrecht, The Netherlands
Gert J. de Borst
3Department of Vascular Surgery, University Medical Center Utrecht, University Utrecht, Utrecht, The Netherlands
Dominique P. V. de Kleijn
3Department of Vascular Surgery, University Medical Center Utrecht, University Utrecht, Utrecht, The Netherlands
Koen H. M. Prange
4Division of BioTherapeutics, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands
Menno P. J. de Winther
4Division of BioTherapeutics, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands
Johan Kuiper
4Division of BioTherapeutics, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands
Mete Civelek
5Center for Public Health Genomics, University of Virginia, Charlottesville, VA 22908, USA
6Department of Biomedical Engineering, University of Virginia, Charlottesville, VA 22908, USA
Sander W. van der Laan
2Central Diagnostic Laboratory, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
Steve Horvath
7Department of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA
8Department of Biostatistics, Fielding School of Public Health, University of California, Los Angeles, Los Angeles, CA, USA
9Altos Labs, Cambridge Institute of Science, Cambridge, UK
Charlotte Onland-Moret
10Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, 3508 GA Utrecht, Utrecht University, Utrecht, The Netherlands
Michal Mokry
2Central Diagnostic Laboratory, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
Gerard Pasterkamp
2Central Diagnostic Laboratory, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
Hester M. den Ruijter
1Laboratory of Experimental Cardiology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
Data Availability
All data and scripts for replication of this study could be provided upon reasonable request.
Posted February 18, 2023.
Atherosclerotic plaque epigenetic age acceleration is characterized by mesenchymal reprogramming and poor prognosis
Robin J. G. Hartman, Ernest Diez Benavente, Lotte Slenders, Arjan Boltjes, Barend M. Mol, Gert J. de Borst, Dominique P. V. de Kleijn, Koen H. M. Prange, Menno P. J. de Winther, Johan Kuiper, Mete Civelek, Sander W. van der Laan, Steve Horvath, Charlotte Onland-Moret, Michal Mokry, Gerard Pasterkamp, Hester M. den Ruijter
medRxiv 2023.02.16.23286067; doi: https://doi.org/10.1101/2023.02.16.23286067
Atherosclerotic plaque epigenetic age acceleration is characterized by mesenchymal reprogramming and poor prognosis
Robin J. G. Hartman, Ernest Diez Benavente, Lotte Slenders, Arjan Boltjes, Barend M. Mol, Gert J. de Borst, Dominique P. V. de Kleijn, Koen H. M. Prange, Menno P. J. de Winther, Johan Kuiper, Mete Civelek, Sander W. van der Laan, Steve Horvath, Charlotte Onland-Moret, Michal Mokry, Gerard Pasterkamp, Hester M. den Ruijter
medRxiv 2023.02.16.23286067; doi: https://doi.org/10.1101/2023.02.16.23286067
Subject Area
Subject Areas
- Addiction Medicine (399)
- Allergy and Immunology (708)
- Anesthesia (201)
- Cardiovascular Medicine (2921)
- Dermatology (249)
- Emergency Medicine (439)
- Epidemiology (12717)
- Forensic Medicine (12)
- Gastroenterology (827)
- Genetic and Genomic Medicine (4569)
- Geriatric Medicine (416)
- Health Economics (728)
- Health Informatics (2913)
- Health Policy (1068)
- Hematology (387)
- HIV/AIDS (923)
- Medical Education (423)
- Medical Ethics (115)
- Nephrology (468)
- Neurology (4341)
- Nursing (234)
- Nutrition (637)
- Oncology (2264)
- Ophthalmology (643)
- Orthopedics (258)
- Otolaryngology (324)
- Pain Medicine (278)
- Palliative Medicine (83)
- Pathology (500)
- Pediatrics (1196)
- Primary Care Research (494)
- Public and Global Health (6922)
- Radiology and Imaging (1524)
- Respiratory Medicine (915)
- Rheumatology (437)
- Sports Medicine (383)
- Surgery (486)
- Toxicology (60)
- Transplantation (210)
- Urology (179)